Epilepsy device pushes up Cyberonics sales
This article was originally published in Clinica
Cyberonics, which markets an implantable vagus nerve stimulation device for epilepsy treatment, has recorded a 287% sales increase to $1.1 million in the first quarter. $554,000 of the sales were generated in the US, where the product, known as the NeuroCybernetic Prosthesis system, was launched this summer (see Clinica No 766, p 15).
You may also be interested in...
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.